Cargando…
The drebrin/EB3 pathway drives invasive activity in prostate cancer
Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate can...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537610/ https://www.ncbi.nlm.nih.gov/pubmed/28319065 http://dx.doi.org/10.1038/onc.2017.45 |
_version_ | 1783254214834651136 |
---|---|
author | Dart, A E Worth, D C Muir, G Chandra, A Morris, J D McKee, C Verrill, C Bryant, R J Gordon-Weeks, P R |
author_facet | Dart, A E Worth, D C Muir, G Chandra, A Morris, J D McKee, C Verrill, C Bryant, R J Gordon-Weeks, P R |
author_sort | Dart, A E |
collection | PubMed |
description | Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression. |
format | Online Article Text |
id | pubmed-5537610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-55376102017-08-07 The drebrin/EB3 pathway drives invasive activity in prostate cancer Dart, A E Worth, D C Muir, G Chandra, A Morris, J D McKee, C Verrill, C Bryant, R J Gordon-Weeks, P R Oncogene Original Article Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression. Nature Publishing Group 2017-07-20 2017-03-20 /pmc/articles/PMC5537610/ /pubmed/28319065 http://dx.doi.org/10.1038/onc.2017.45 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Dart, A E Worth, D C Muir, G Chandra, A Morris, J D McKee, C Verrill, C Bryant, R J Gordon-Weeks, P R The drebrin/EB3 pathway drives invasive activity in prostate cancer |
title | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
title_full | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
title_fullStr | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
title_full_unstemmed | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
title_short | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
title_sort | drebrin/eb3 pathway drives invasive activity in prostate cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537610/ https://www.ncbi.nlm.nih.gov/pubmed/28319065 http://dx.doi.org/10.1038/onc.2017.45 |
work_keys_str_mv | AT dartae thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT worthdc thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT muirg thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT chandraa thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT morrisjd thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT mckeec thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT verrillc thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT bryantrj thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT gordonweekspr thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT dartae drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT worthdc drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT muirg drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT chandraa drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT morrisjd drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT mckeec drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT verrillc drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT bryantrj drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT gordonweekspr drebrineb3pathwaydrivesinvasiveactivityinprostatecancer |